Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma
Status:
Unknown status
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
This study investigates toxicity and efficacy of 2 x R-DHAP followed by High dose
chemotherapy R-TEC and autologous stem cell transplantation in patients with relapsed or
refractory aggressive Non- Hodgkins's Lymphoma.